---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005501"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:19:58.705258+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiNK Q2 net loss $6.1M; cash $29.8M; DARPA selects AgenT-797; clinical data updates expected 2H22

## Summary
- Cash $29.8M as of June 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $4.6M for Q2.
- Net loss $6.1M ($0.18/share) vs $6.3M ($0.26/share) in Q2 2021; R&D spend $5.9M vs $3.6M.
- AgenT-797 clinical data updates in solid tumors, myeloma and viral ARDS planned for 2H2022.
- AgenT-797 identified as selectable for DARPA funding; contract negotiations underway.
- Internal cGMP manufacturing completed with capacity to treat >700,000 patients/year; Dr. Joy Zhou appointed VP CMC.

## SEC filing metadata
- accession: 0001171843-22-005501
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184322005501/0001171843-22-005501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184322005501/f8k_080922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005501
- JSON: https://secwatch.observer/filing/0001171843-22-005501.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005501.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.